Good morning :)
$
₹
Laboratory Corporation of America Holdings

Laboratory Corporation of America Holdings

LH

NYSE
Asset Logo

Laboratory Corporation of America Holdings

LH

NYSE
$327.460.45% (-1.48)
$
₹
$327.460.45% (-1.48)
High
—
—
Low
—
—
Returns
—
—
Loading...
1D
1W
1M
3M
6M
1Y
3Y
5Y
Max

Healthcare

Diagnostics & Research

Large Cap

With a market cap of $26.7B the stock is ranked 526

Key Metrics

Key Metrics

PE TTM
PE TTM

Close price divided by the earnings per share for the trailing twelve months

27.20
PB
PB

Close price divided by the book value per share at the end of the most recent quarter

2.93
EPS TTM
EPS TTM

Net profit earned per share over the trailing twelve months (sum of the last 4 quarters)

$12.09
PEG Ratio
PEG Ratio

Price-to-Earnings (P/E) ratio divided by the forecasted annual earnings per share (EPS) growth rate over the next five years

1.21
Profit Margin
Profit Margin

Net profit divided by the total revenue for the most recent financial year

6.99%
Dividend Yield
Dividend Yield

Annual dividend per share for the trailing twelve months divided by the close price

0.87%

Analyst Ratings & Forecast

Analyst Ratings & Forecast

Detailed Forecast Detailed Forecast 

Based on 18 analysts reports

Buy
13 analysts
Hold
4 analysts
Sell
1 analyst

Price Upside

+4.92%

Earnings Growth

+11.61%

Rev. Growth

+5.72%

See Detailed Forecast

Company Profile

Company Profile

Labcorp Holdings Inc. provides laboratory services. It operates in Diagnostics Laboratories and Biopharma Laboratory Services segments. The company offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, PAP tests, hemoglobin A1C, PSA, tests for sexually transmitted diseases, vitamin D testing, microbiology cultures and procedures, and alcohol and other substance abuse tests. It also provides specialty testing services comprising gene-based and esoteric testing; advanced tests target specific diseases; services related to anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, parentage and donor testing, occupational testing service, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests; and health and wellness services to employers and managed care organizations. In addition, it offers digital pathology solutions, a pathology platforms that support the digitization, centralized review, and sharing of pathology slides; provider and payer digital platforms, an online applications for providers, MCOs, and ACOs; online and mobile applications that enable patients to check offerings, schedule PSC visits, check-in upon PSC arrival, complete documentation, access tests and test results, and manage their accounts; and Generative AI enabled Test Selection, a generative AI enabled tool. It serves clients, third party, medicare/medicaid, patients, pharmaceutical, biotechnology, medical device, diagnostic companies, and CROs. It has a collaboration with the Children's Hospital of Philadelphia to accelerate the discovery, development, and availability of pediatric diagnostics. The company was founded in 1995 and is headquartered in Burlington, North Carolina.
Labcorp Holdings Inc. provides laboratory services. It operates in Diagnostics Laboratories and Biopharma Laboratory Services segments. The company offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, PAP tests, hemoglobin A1C, PSA, tests for sexually transmitted diseases, vitamin D testing, microbiology cultures and procedures, and alcohol and other substance abuse tests. It also provides specialty testing services comprising gene-based and esoteric testing; advanced tests target specific diseases; services related to anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, parentage and donor testing, occupational testing service, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests; and health and wellness services to employers and managed care organizations. In addition, it offers digital pathology solutions, a pathology platforms that support the digitization, centralized review, and sharing of pathology slides; provider and payer digital platforms, an online applications for providers, MCOs, and ACOs; online and mobile applications that enable patients to check offerings, schedule PSC visits, check-in upon PSC arrival, complete documentation, access tests and test results, and manage their accounts; and Generative AI enabled Test Selection, a generative AI enabled tool. It serves clients, third party, medicare/medicaid, patients, pharmaceutical, biotechnology, medical device, diagnostic companies, and CROs. It has a collaboration with the Children's Hospital of Philadelphia to accelerate the discovery, development, and availability of pediatric diagnostics. The company was founded in 1995 and is headquartered in Burlington, North Carolina.

Peers

Compare with peers Compare with peers 

Peers

Compare with peers Compare with peers 
CVS Health Corp
CVS
CVS Health Corp
P/E Ratio
24.59
24.59
1Y Return
15.29%
15.29%
Buy Reco %
92.59
92.59
Cigna Corp
CI
Cigna Corp
P/E Ratio
12.68
12.68
1Y Return
0.61%
0.61%
Buy Reco %
75.00
75.00
Quest Diagnostics Incorporated
DGX
Quest Diagnostics Incorporated
P/E Ratio
24.09
24.09
1Y Return
32.01%
32.01%
Buy Reco %
52.94
52.94
Guardant Health Inc
GH
Guardant Health Inc
P/E Ratio
—
—
1Y Return
143.8%
143.8%
Buy Reco %
96.15
96.15
BrightSpring Health Services, Inc. Common Stock
BTSG
BrightSpring Health Services, Inc. Common Stock
P/E Ratio
53.19
53.19
1Y Return
79.43%
79.43%
Buy Reco %
100.00
100.00
Compare with Peers

Forecast

Forecast

Price

Revenue

Earnings

Price Forecast

Price Forecast

Lower price growth forecast versus trailing 3-year CAGR
Compares analyst forecast growth with historical annualized growth.

The 12-month consensus target implies 4.92% growth, versus a trailing 3-year CAGR of 19.54%.

2026
Current$328.95Baseline
Analyst Target - 1 year
Target$345.13+4.92%

All values in $

202220232024202520262027$226.49$277.54$328.59Target+4.92%
2026
Current$328.95Baseline
Analyst Target - 1 year
Target$345.13+4.92%

All values in $

Revenue Forecast

Revenue Forecast

Higher revenue growth forecast versus trailing 3-year CAGR
Compares analyst forecast growth with historical annualized growth.

The next fiscal year's mean estimate implies 5.72% growth, versus a trailing 3-year CAGR of 5.55%.

2025
Current$13.95Baseline
Forecast for Dec 2026
High$14.79+6.01%
Average$14.74+5.72%
Low$14.72+5.52%

All values in $ Billion

20212022202320242025202613.1311.8612.1613.0013.95Low+5.52%Average+5.72%High+6.01%
2025
Current$13.95Baseline
Forecast for Dec 2026
High$14.79+6.01%
Average$14.74+5.72%
Low$14.72+5.52%

All values in $ Billion

Earnings Per Share Forecast

Earnings Per Share Forecast

Higher earnings growth forecast versus trailing 3-year CAGR
Compares analyst forecast growth with historical annualized growth.

The next fiscal year's mean estimate implies 11.61% growth, versus a trailing 3-year CAGR of -6.15%.

2025
Current$16.44Baseline
Forecast for Dec 2026
High$18.5+12.53%
Average$18.35+11.61%
Low$18.1+10.1%

All values in $

20212022202320242025202628.5119.8913.9214.5716.44Low+10.1%Average+11.61%High+12.53%
2025
Current$16.44Baseline
Forecast for Dec 2026
High$18.5+12.53%
Average$18.35+11.61%
Low$18.1+10.1%

All values in $

Financials

Financials

Income

Balance Sheet

Cash Flow

3.5
0.2
3.5
0.1
3.5
0.2
3.7
0.2
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Revenue
Net Income
Financial YearQ1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026
Total Revenue3.173.223.283.323.343.523.563.513.533.73
Net Income0.220.200.160.140.210.230.260.160.270.29
Net Profit Margin7.17%6.37%5.15%4.30%6.36%6.74%7.32%4.68%7.85%8.00%
See CostsAll values in $ Billion

Peers

Peers & Comparison

Peers & Comparison

Comparing 2 stocks from
HealthcareDiagnostics & Research

Valuation

Returns

Forecast

ScreenerCompare valuation on Screener
StockPE TTMPE TTMPBPBPEG RatioPEG Ratio
Laboratory Corporation of America Holdings 27.202.931.21
CVS Health Corp24.591.440.21
Cigna Corp12.681.710.75
ScreenerCompare valuation on Screener

Price Comparison

Price Comparison

Compare LH with any stock or ETF
Compare LH with any stock or ETF
Comparing from
LH
CVS
CI
Loading...

Frequently asked questions

  1. Laboratory Corporation of America Holdings (LH) share price today is $327.46 as of October 27, 2026 at 12:25 AM IST. The stock touched a day high of $331.60 and a day low of $327.37.

  2. Laboratory Corporation of America Holdings stock trades on NYSE under the ticker symbol LH.

  3. Laboratory Corporation of America Holdings's market capitalization is $26.67B as of October 27, 2026 at 12:25 AM IST.

  4. Laboratory Corporation of America Holdings's price-to-earnings (P/E) ratio is 27.20 as of October 26, 2026.

  5. Laboratory Corporation of America Holdings's price-to-book (P/B) ratio is 2.93 as of October 26, 2026.

  6. Yes, Laboratory Corporation of America Holdings pays a dividend, with a current dividend yield of 0.87%.

  7. Yes, You can buy Laboratory Corporation of America Holdings shares from India through Tickertape, via our partnership with ViewTrade IFSC under the IFSCA Global Access framework, subject to RBI’s Liberalised Remittance Scheme (LRS) limits.

  8. Indian investors can buy Laboratory Corporation of America Holdings shares in three steps: 1. Search Laboratory Corporation of America Holdings on the Tickertape app and tap Invest. 2. Complete your one-time digital KYC. 3. Fund your account and buy from as low as $1 via fractional shares.

  9. Since Laboratory Corporation of America Holdings trades in USD, an Indian investor's INR returns depend on both the stock's price movement and the USD-INR exchange rate. If the rupee depreciates against the dollar, INR returns are boosted beyond the stock's USD return; if the rupee appreciates, INR returns are reduced.

  10. Indian investors can start investing in Laboratory Corporation of America Holdings (LH) shares from as little as $1 through fractional ownership on Tickertape - for example, $10 buys approximately 0.0305 shares at the current price of $327.46.

Loading...